FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317568049> ?p ?o ?g. }

• W4317568049 endingPage "778" @default.
• W4317568049 startingPage "769" @default.
• W4317568049 abstract "Abstract Background Initiating same-day ART for newly HIV-diagnosed individuals reduces secondary HIV transmissions and the risk of them being lost to follow-up between diagnosis and initiation of ART. Methods The FAST study was a national, prospective, single-arm study assessing the efficacy, safety and feasibility of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in a same-day initiation model. ART had to be started on the first medical appointment, before any laboratory results were available. Participants completed a self-administered questionnaire at each visit including a HIV anxiety 5-point Likert scale. The primary outcome was the proportion of participants in the ITT population with plasma HIV RNA (pVL) &lt; 50 copies/mL at Week (W) 24 using the FDA Snapshot algorithm. Results Overall, 112 participants were included in the ITT population. During follow-up, seven participants discontinued the study drug but remained on the study, and seven others discontinued follow-up. According to FDA Snapshot analysis, at W24 and W48, 90/112, (80.4%; 95% CI: 71.8–87.3) and 95/112 (84.8%; 95% CI: 76.8–90.9) of participants achieved pVL &lt; 50 copies/mL, respectively. The protocol-defined virological failure (PDVF, 2 consecutive pVL ≥ 50 copies/mL as of W24) was observed in 11/112 (9.8%) at W24 and 14/112 (12.5%) at W48. No emergent resistance-associated mutation was detected in those with PDVF at W24 and W48. BIC/FTC/TAF was well tolerated through to W48, with a low incidence of grade 3–4 adverse events (15/100 person-years). Patient opinion of same-day treatment initiation and continuing BIC/FTC/TAF was very favourable. Conclusions These results suggest that BIC/FTC/TAF is safe, effective and well accepted for same-day initiation." @default.
• W4317568049 created "2023-01-21" @default.
• W4317568049 creator A5015530333 @default.
• W4317568049 creator A5016215468 @default.
• W4317568049 creator A5023111858 @default.
• W4317568049 creator A5028889647 @default.
• W4317568049 creator A5029770079 @default.
• W4317568049 creator A5035641158 @default.
• W4317568049 creator A5047124634 @default.
• W4317568049 creator A5059602594 @default.
• W4317568049 creator A5061527531 @default.
• W4317568049 creator A5063610325 @default.
• W4317568049 creator A5068393150 @default.
• W4317568049 creator A5068809984 @default.
• W4317568049 creator A5070585467 @default.
• W4317568049 creator A5081988720 @default.
• W4317568049 creator A5091495073 @default.
• W4317568049 date "2023-01-20" @default.
• W4317568049 modified "2023-10-06" @default.
• W4317568049 title "Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study—IMEA 055" @default.
• W4317568049 cites W2004493436 @default.
• W4317568049 cites W2106786687 @default.
• W4317568049 cites W2238552371 @default.
• W4317568049 cites W2311215932 @default.
• W4317568049 cites W2475857717 @default.
• W4317568049 cites W2554174936 @default.
• W4317568049 cites W2562227274 @default.
• W4317568049 cites W2586083164 @default.
• W4317568049 cites W2752494178 @default.
• W4317568049 cites W2753489952 @default.
• W4317568049 cites W2759356460 @default.
• W4317568049 cites W2804518933 @default.
• W4317568049 cites W2898542399 @default.
• W4317568049 cites W2899935160 @default.
• W4317568049 cites W2915372808 @default.
• W4317568049 cites W2979917028 @default.
• W4317568049 cites W2996920874 @default.
• W4317568049 cites W3028663891 @default.
• W4317568049 cites W3036631329 @default.
• W4317568049 cites W3094950797 @default.
• W4317568049 cites W3170882379 @default.
• W4317568049 doi "https://doi.org/10.1093/jac/dkad008" @default.
• W4317568049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36659824" @default.
• W4317568049 hasPublicationYear "2023" @default.
• W4317568049 type Work @default.
• W4317568049 citedByCount "2" @default.
• W4317568049 countsByYear W43175680492023 @default.
• W4317568049 crossrefType "journal-article" @default.
• W4317568049 hasAuthorship W4317568049A5015530333 @default.
• W4317568049 hasAuthorship W4317568049A5016215468 @default.
• W4317568049 hasAuthorship W4317568049A5023111858 @default.
• W4317568049 hasAuthorship W4317568049A5028889647 @default.
• W4317568049 hasAuthorship W4317568049A5029770079 @default.
• W4317568049 hasAuthorship W4317568049A5035641158 @default.
• W4317568049 hasAuthorship W4317568049A5047124634 @default.
• W4317568049 hasAuthorship W4317568049A5059602594 @default.
• W4317568049 hasAuthorship W4317568049A5061527531 @default.
• W4317568049 hasAuthorship W4317568049A5063610325 @default.
• W4317568049 hasAuthorship W4317568049A5068393150 @default.
• W4317568049 hasAuthorship W4317568049A5068809984 @default.
• W4317568049 hasAuthorship W4317568049A5070585467 @default.
• W4317568049 hasAuthorship W4317568049A5081988720 @default.
• W4317568049 hasAuthorship W4317568049A5091495073 @default.
• W4317568049 hasConcept C126322002 @default.
• W4317568049 hasConcept C142462285 @default.
• W4317568049 hasConcept C159047783 @default.
• W4317568049 hasConcept C187212893 @default.
• W4317568049 hasConcept C2779778239 @default.
• W4317568049 hasConcept C2908647359 @default.
• W4317568049 hasConcept C2993143319 @default.
• W4317568049 hasConcept C3013748606 @default.
• W4317568049 hasConcept C71924100 @default.
• W4317568049 hasConcept C99454951 @default.
• W4317568049 hasConceptScore W4317568049C126322002 @default.
• W4317568049 hasConceptScore W4317568049C142462285 @default.
• W4317568049 hasConceptScore W4317568049C159047783 @default.
• W4317568049 hasConceptScore W4317568049C187212893 @default.
• W4317568049 hasConceptScore W4317568049C2779778239 @default.
• W4317568049 hasConceptScore W4317568049C2908647359 @default.
• W4317568049 hasConceptScore W4317568049C2993143319 @default.
• W4317568049 hasConceptScore W4317568049C3013748606 @default.
• W4317568049 hasConceptScore W4317568049C71924100 @default.
• W4317568049 hasConceptScore W4317568049C99454951 @default.
• W4317568049 hasFunder F4320308573 @default.
• W4317568049 hasIssue "3" @default.
• W4317568049 hasLocation W43175680491 @default.
• W4317568049 hasLocation W43175680492 @default.
• W4317568049 hasOpenAccess W4317568049 @default.
• W4317568049 hasPrimaryLocation W43175680491 @default.
• W4317568049 hasRelatedWork W1973460911 @default.
• W4317568049 hasRelatedWork W2088807081 @default.
• W4317568049 hasRelatedWork W2096903645 @default.
• W4317568049 hasRelatedWork W2134624998 @default.
• W4317568049 hasRelatedWork W2149708245 @default.
• W4317568049 hasRelatedWork W2318890478 @default.
• W4317568049 hasRelatedWork W2335284617 @default.
• W4317568049 hasRelatedWork W2782579039 @default.
• W4317568049 hasRelatedWork W2975872300 @default.

• next